Summary •Lymphoseek continues to gain new market opportunities. •Oxford loan enhances financial flexibility. •Short interest has been trending down. •However, gains in the stock price itself continue to be elusive.
To be blunt, Navidea Biopharmaceuticals (NAVB) has been a poor performer over the past year. Furthermore, anyone who reasoned as I did and saw the share price movement following the Crede financing deal last October as a buying opportunity, is likely looking at a loss now unless the managed to buy near the bottom. Pro subscribers can see the article here....more .. Lymphoseek on Track to Take Market Share
Since receiving a temporary CMS reimbursement pass through C-code on October 1st last year, sales of Lymphoseek (LS) have begun to ramp up nicely. President and Chief Business Officer Dr. Thomas H. Tulip noted on the Q4 2013 conference call that 80% of customers have reordered and had this reassurance about market penetration rates:
“ I've looked for comparisons and found a few innovative premium price therapeutics launched in recent years[.]... The very best disease launches leading to very substantive sales of well-known products did not exceed 10% market share after the first year on the market. So Lymphoseek compares well as we will certainly get beyond 10% penetration in the first year.
This, along with the reiterating the projection for LS to reach a majority market share within 10 to 14 months....more... .. I have long since given up on trying to time this stock or offer short term guidance, but Navidea continues to execute very well in my opinion. Hopefully, someday in the not-too-distant future, its stock will reflect that
News 
Market Data 
Discover 
AI
